Gilead Sciences Q2: The New Drug That Could Change Everything

Gilead Sciences reported stronger-than-expected Q2 2025 results, with revenue of $7.08 billion and adjusted EPS of $2.01, primarily driven by robust performance from its dominant HIV portfolio, particularly Biktarvy. The company raised its full-year guidance, reflecting continued strength and the significant potential of Yeztugo, its newly FDA-approved 6-month injectable HIV PrEP, which is poised to expand the prevention market due to enhanced convenience. This, alongside stable cash flows from its HIV franchise through 2033 and growth in oncology, supports the company's current valuation and an analyst consensus target price of $133.

Analysis

Gilead Sciences (GILD) delivered a strong second quarter for 2025, beating consensus with revenue of $7.08 billion and an adjusted EPS of $2.01, prompting an upward revision of its full-year 2025 guidance. The performance was anchored by the robust HIV franchise, which grew 7% year-over-year to $5.1 billion, led by Biktarvy's 9.2% sales increase to $3.53 billion. The patent protection for Biktarvy until 2033 provides nearly a decade of visibility into the company's primary cash flow stream. The most significant strategic development is the FDA approval of Yeztugo, a twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP) that offers a substantial convenience advantage over daily pills or GSK's bimonthly Apretude. This new product is positioned to significantly expand the PrEP market, where currently only one-third of the 1.2 million eligible individuals in the U.S. participate. Financially, Gilead exhibits strength with adjusted gross margins improving to 86.9%, operating margins exceeding 46%, and a free cash flow yield over 7%. Despite this, the company trades at a 13.78x forward P/E, a discount to the sector median of 16.74x, and a forward PEG ratio of 0.65, suggesting potential for revaluation. While the oncology division shows promise with Trodelvy sales up 14%, headwinds persist in CAR-T therapies, with sales down 7% due to competitive pressures.

Key Decisions for Investors

• Investors should consider the stock's compelling risk/return profile, supported by durable cash flows from its HIV franchise which is secured by patent protection until 2033, and a valuation that remains at a discount to the sector on an EV/EBITDA basis.
• The primary near-term catalyst to monitor is the market adoption rate of the new HIV PrEP drug, Yeztugo, as its success is critical for expanding the addressable market and validating the company's growth narrative beyond Biktarvy.
• It is prudent to track the performance of the oncology portfolio, particularly Trodelvy's progress in new indications, as successful diversification is key to mitigating the risk associated with Gilead's high revenue concentration in the HIV market.
• For income-oriented investors, the 2.83% dividend yield, which is substantially above the sector average, provides a steady cash return while the company executes on its long-term growth catalysts.